Mtove George, Kimani Joshua, Kisinza William, Makenga Geofrey, Mangesho Peter, Duparc Stephan, Nakalembe Miriam, Phiri Kamija S, Orrico Russell, Rojo Ricardo, Vandenbroucke Pol
National Institute for Medical Research, Amani Medical Research Centre, Muheza, Tanzania.
College of Health Sciences, University of Nairobi, Nairobi, Kenya.
Trials. 2018 Mar 22;19(1):190. doi: 10.1186/s13063-018-2563-1.
Multinational clinical trials are logistically complex and require close coordination between various stakeholders. They must comply with global clinical standards and are accountable to multiple regulatory and ethical bodies. In resource-limited settings, it is challenging to understand how to apply global clinical standards to international, national, and local factors in clinical trials, making multiple-level stakeholder engagement an important element in the successful conduct of these clinical trials.
During the planning and implementation of a large multinational clinical trial for intermittent preventive treatment of malaria in pregnancy in resource-limited areas of sub-Saharan Africa, we encountered numerous challenges, which required implementation of a range of engagement measures to ensure compliance with global clinical and regulatory standards. These challenges included coordination with ongoing global malaria efforts, heterogeneity in national regulatory structures, sub-optimal healthcare infrastructure, local practices and beliefs, and perspectives that view healthcare providers with undue trust or suspicion. In addition to engagement with international bodies, such as the World Health Organization, the Malaria in Pregnancy Consortium, the Steve Biko Centre for Bioethics, and the London School of Hygiene and Tropical Medicine, in order to address the challenges just described, Pfizer Inc. and Medicines for Malaria Venture (the "Sponsoring Entities" for these studies) and investigators liaised with national- and district-level stakeholders such as health ministers and regional/local community health workers. Community engagement measures undertaken by investigators included local meetings with community leaders to explain the research aims and answer questions and concerns voiced by the community. The investigators also engaged with family members of prospective trial participants in order to be sensitive to local practices and beliefs.
Engagement with key stakeholders at international and national levels enabled the Sponsoring Entities to address challenges by aligning the study design with the requirements of health and regulatory agencies and to understand and address healthcare infrastructure needs prior to trial initiation. Local stakeholder engagement, including community members, study participants, and family enabled the investigators to address challenges by ensuring that study design and conduct were adapted to local considerations and ensuring accurate information about the study aims was shared with the public.
ClinicalTrials.gov, ID: NCT01103063 . Registered on 7 April 2010.
跨国临床试验在后勤方面十分复杂,需要各利益相关方密切协调。它们必须遵守全球临床标准,并对多个监管和伦理机构负责。在资源有限的环境中,理解如何将全球临床标准应用于临床试验中的国际、国家和地方因素具有挑战性,这使得多层次利益相关方的参与成为这些临床试验成功开展的重要因素。
在撒哈拉以南非洲资源有限地区为孕期疟疾间歇性预防治疗开展一项大型跨国临床试验的规划和实施过程中,我们遇到了诸多挑战,这需要实施一系列参与措施以确保符合全球临床和监管标准。这些挑战包括与正在进行的全球疟疾防治工作的协调、国家监管结构的异质性、次优的医疗基础设施、当地的做法和信仰,以及对医疗服务提供者过度信任或怀疑的观点。除了与国际机构(如世界卫生组织、孕期疟疾联盟、史蒂夫·比科生物伦理中心和伦敦卫生与热带医学院)合作外,为应对上述挑战,辉瑞公司和疟疾药物事业会(这些研究的“发起实体”)以及研究人员与国家和地区层面的利益相关方(如卫生部长和地区/当地社区卫生工作者)进行了联络。研究人员采取的社区参与措施包括与社区领袖举行当地会议,解释研究目的并回答社区提出的问题和关切。研究人员还与潜在试验参与者的家庭成员进行了沟通,以便对当地的做法和信仰保持敏感。
与国际和国家层面的关键利益相关方的合作使发起实体能够通过使研究设计符合卫生和监管机构的要求来应对挑战,并在试验启动前了解和满足医疗基础设施需求。包括社区成员、研究参与者和家庭在内与当地利益相关方的合作使研究人员能够通过确保研究设计和实施适应当地情况,并确保向公众分享有关研究目的的准确信息来应对挑战。
ClinicalTrials.gov,标识符:NCT01103063。于2010年4月7日注册。